Article info
Commentary
Selective LOXL2 inhibition: potent antifibrotic effects in ongoing fibrosis and fibrosis regression
- Correspondence to Professor Jonel Trebicka, European Foundation for the Study of Chronic Liver Failure, Travessera de Gràcia, 11, 7th floor, Barcelona 08021, Spain; jonel.trebicka{at}efclif.com
Citation
Selective LOXL2 inhibition: potent antifibrotic effects in ongoing fibrosis and fibrosis regression
Publication history
- Received January 31, 2017
- Revised February 8, 2017
- Accepted February 9, 2017
- First published February 28, 2017.
Article Versions
- Previous version (28 February 2017).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/